摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(4-Dimethylaminophenyl)-3-methyl-2-pyrazolin-5-one | 602297-86-9

中文名称
——
中文别名
——
英文名称
1-(4-Dimethylaminophenyl)-3-methyl-2-pyrazolin-5-one
英文别名
2-[4-(dimethylamino)phenyl]-5-methyl-4H-pyrazol-3-one
1-(4-Dimethylaminophenyl)-3-methyl-2-pyrazolin-5-one化学式
CAS
602297-86-9
化学式
C12H15N3O
mdl
——
分子量
217.271
InChiKey
JKEWJTOBDLUVMN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    412.2±28.0 °C(Predicted)
  • 密度:
    1.14±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.4
  • 重原子数:
    16
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    35.9
  • 氢给体数:
    0
  • 氢受体数:
    3

文献信息

  • PREVENTIVE AND/OR THERAPEUTIC DRUGS FOR INFLAMMATORY INTESTINAL DISEASES
    申请人:Mitsubishi Pharma Corporation
    公开号:EP1553087A1
    公开(公告)日:2005-07-13
    The object of the present invention is to provide a medicament useful for preventing and/or treating inflammatory bowel disease. The present invention provides a medicament for preventing and/or treating inflammatory bowel disease which comprises as an active ingredient a pyrazolone derivative represented by the following formula (I) or a physiologically acceptable salt thereof, or a hydrate thereof or a solvate thereof: wherein R1 represents a hydrogen atom, an aryl group, an alkyl group, or an alkoxycarbonylalkyl group; R2 represents a hydrogen atom, an aryloxy group, an arylmercapto group, an alkyl group or a hydroxyalkyl group; or R1 and R2 are combined with each other to represent an alkylene group; and R3 represents a hydrogen atom, an alkyl group, a cycloalkyl group, a hydroxyalkyl group, a benzyl group, a naphthyl group, a phenyl group, or a phenyl group substituted with 1 to 3 substituents selected from the group consisting of an alkyl group, an alkoxy group, a hydroxyalkyl group, an alkoxycarbonyl group, an alkylmercapto group, an alkylamino group, a dialkylamino group, a halogen atom, a trifluoromethyl group, a carboxyl group, a cyano group, a hydroxyl group, a nitro group, an amino group and an acetamide group.
    本发明的目的是提供一种用于预防和/或治疗炎性肠病的药物。本发明提供了一种药物,用于预防和/或治疗炎性肠病,其包括以下式(I)所表示的吡唑酮衍生物作为活性成分,或其生理上可接受的盐,或其合物或溶剂化合物:其中R1表示氢原子,芳基,烷基或烷氧羰基烷基;R2表示氢原子,芳氧基,芳基,烷基或羟基烷基;或R1和R2结合在一起表示烷基;R3表示氢原子,烷基,环烷基,羟基烷基,苄基,基,苯基或苯基,其被1至3个取代基所取代,所述取代基被选自羟基烷基,烷氧基,羟基烷氧基,烷氧羰基,烷基,烷基基,二烷基基,卤素原子,三甲基基团,羧基,基,羟基,硝基,基和乙酰胺基。
  • AGENT FOR PREVENTING AND/OR TREATING OPHTHALMOLOGIC DISEASES
    申请人:MITSUBISHI TANABE PHARMA CORPORATION
    公开号:US20170273949A1
    公开(公告)日:2017-09-28
    It is an object of the present invention to provide a novel medicament for preventing and/or treating ophthalmologic diseases caused by ocular angiogenesis. According to the present invention, provided is a medicament for preventing and/or treating ophthalmologic diseases caused by ocular angiogenesis, which comprises, as an active ingredient, a pyrazolone derivative such as 3-methyl-1-phenyl-2-pyrazolin-5-one, or a physiologically acceptable salt thereof, or a hydrate thereof or a solvate thereof.
    本发明的目的是提供一种新型药物,用于预防和/或治疗由眼部血管生成引起的眼科疾病。根据本发明,提供了一种用于预防和/或治疗由眼部血管生成引起的眼科疾病的药物,其包括作为活性成分的吡唑酮衍生物,如3-甲基-1-苯基-2-吡唑啉-5-酮,或其生理上可接受的盐,或其合物或溶剂化物。
  • Medicament for prevention and/or therapy of arterial wall disorder
    申请人:——
    公开号:US20040254234A1
    公开(公告)日:2004-12-16
    An object of the present invention is to provide a medicament and method which is useful for prevention and/or therapy of arterial wall injury. According to the present invention, there is provided a method for prevention and/or therapy of arterial wall injury which comprises a step of administering the pyrazolone derivative represented by the following formula (I) or the physiologically acceptable salt thereof, or the hydrate or solvate thereof in a preventively or therapeutically effective amount to mammals including humans: 1 wherein R 1 represents a hydrogen atom, an aryl group, an alkyl group, or an alkoxycarbonylalkyl group; R 2 represents a hydrogen atom, an aryloxy group, an arylmercapto group, an alkyl group or a hydroxyalkyl group; or R 1 and R 2 are combined with each other to represent an alkylene group; and R 3 represents a hydrogen atom, an alkyl group, a cycloalkyl group, a hydroxyalkyl group, a benzyl group, a naphthyl group, a phenyl group, or a phenyl group substituted with 1 to 3 substituents selected from the group consisting of an alkyl group, an alkoxy group, a hydroxyalkyl group, an alkoxycarbonyl group, an alkylmercapto group, an alkylamino group, a dialkylamino group, a halogen atom, a trifluoromethyl group, a carboxyl group, a cyano group, a hydroxyl group, a nitro group, an amino group and an acetamide group.
    本发明的目的是提供一种药物和方法,用于预防和/或治疗动脉壁损伤。根据本发明,提供了一种预防和/或治疗动脉壁损伤的方法,包括向哺乳动物,包括人类,预防性或治疗性地给予以下式(I)所表示的吡唑酮衍生物或其生理上可接受的盐,或其合物或溶剂,以预防或治疗有效量:1其中R1表示氢原子,芳基,烷基或烷氧羰基烷基;R2表示氢原子,芳氧基,芳醇基,烷基或羟基烷基;或R1和R2结合在一起表示烷基;R3表示氢原子,烷基,环烷基,羟基烷基,苄基,基,苯基或苯基,其被1至3个取自羟基烷基,烷氧基,烷氧羰基基,烷基,烷基基,二烷基基,卤素原子,三甲基基,羧基,基,羟基,硝基,基和乙酰胺基的取代基所取代。
  • Drugs comprising combination of antithrombotic agent with pyrazolone derivative
    申请人:Yamada Keiichi
    公开号:US20050009896A1
    公开(公告)日:2005-01-13
    It is intended to provide drugs for treating and/or preventing ischemic diseases which are safe and have little side effects. Namely, drugs comprising a combination of an antithrombotic agent and a pyrazolone derivative defined in the description or its pharmaceutically acceptable salt.
    本发明旨在提供一种安全并且副作用小的药物,用于治疗和/或预防缺血性疾病。即,药物包括在说明书中定义的抗血栓药物和吡唑酮衍生物的组合或其药学上可接受的盐。
  • BLOOD-BRAIN BARRIER DISRUPTION INHIBITORS
    申请人:Mitsubishi Pharma Corporation
    公开号:EP1582517A1
    公开(公告)日:2005-10-05
    An object of the present invention is to provide a blood-brain barrier disruption inhibitor. The present invention provides a blood-brain barrier disruption inhibitor which comprises as an active ingredient a pyrazolone derivative represented by the following formula (I) or a physiologically acceptable salt thereof, or a hydrate thereof or a solvate thereof: wherein R1 represents a hydrogen atom, an aryl group, an alkyl group, or an alkoxycarbonylalkyl group; R2 represents a hydrogen atom, an aryloxy group, an arylmercapto group, an alkyl group or a hydroxyalkyl group; or R1 and R2 are combined with each other to represent an alkylene group; and R3 represents a hydrogen atom, an alkyl group, a cycloalkyl group, a hydroxyalkyl group, a benzyl group, a naphthyl group, a phenyl group, or a phenyl group substituted with 1 to 3 substituents selected from the group consisting of an alkyl group, an alkoxy group, a hydroxyalkyl group, an alkoxycarbonyl group, an alkylmercapto group, an alkylamino group, a dialkylamino group, a halogen atom, a trifluoromethyl group, a carboxyl group, a cyano group, a hydroxyl group, a nitro group, an amino group and an acetamide group.
    本发明的目的是提供一种血脑屏障破坏抑制剂。本发明提供了一种血脑屏障破坏抑制剂,其活性成分包括下式(I)代表的吡唑酮衍生物或其生理上可接受的盐,或其合物或其溶液: 其中 R1 代表氢原子、芳基、烷基或烷氧基羰基烷基;R2 代表氢原子、芳氧基、芳巯基、烷基或羟基烷基;或 R1 和 R2 相互结合代表亚烷基;和 R3 代表氢原子、烷基、环烷基、羟烷基、苄基、基、苯基或被 1 至 3 个取代基取代的苯基,取代基可从烷基、烷氧基羟烷基、烷氧羰基、烷基巯基、烷基基、二烷基基、卤素原子、三甲基、羧基、基、羟基、硝基、基和乙酰胺基。
查看更多

同类化合物

(乙腈)二氯镍(II) (R)-(-)-α-甲基组胺二氢溴化物 (N-(2-甲基丙-2-烯-1-基)乙烷-1,2-二胺) (4-(苄氧基)-2-(哌啶-1-基)吡啶咪丁-5-基)硼酸 (11-巯基十一烷基)-,,-三甲基溴化铵 鼠立死 鹿花菌素 鲸蜡醇硫酸酯DEA盐 鲸蜡硬脂基二甲基氯化铵 鲸蜡基胺氢氟酸盐 鲸蜡基二甲胺盐酸盐 高苯丙氨醇 高箱鲀毒素 高氯酸5-(二甲氨基)-1-({(E)-[4-(二甲氨基)苯基]甲亚基}氨基)-2-甲基吡啶正离子 高氯酸2-氯-1-({(E)-[4-(二甲氨基)苯基]甲亚基}氨基)-6-甲基吡啶正离子 高氯酸2-(丙烯酰基氧基)-N,N,N-三甲基乙铵 马诺地尔 马来酸氢十八烷酯 马来酸噻吗洛尔EP杂质C 马来酸噻吗洛尔 马来酸倍他司汀 顺式环己烷-1,3-二胺盐酸盐 顺式氯化锆二乙腈 顺式吡咯烷-3,4-二醇盐酸盐 顺式双(3-甲氧基丙腈)二氯铂(II) 顺式3,4-二氟吡咯烷盐酸盐 顺式1-甲基环丙烷1,2-二腈 顺式-二氯-反式-二乙酸-氨-环己胺合铂 顺式-二抗坏血酸(外消旋-1,2-二氨基环己烷)铂(II)水合物 顺式-N,2-二甲基环己胺 顺式-4-甲氧基-环己胺盐酸盐 顺式-4-环己烯-1.2-二胺 顺式-4-氨基-2,2,2-三氟乙酸环己酯 顺式-3-氨基环丁烷甲腈盐酸盐 顺式-2-羟基甲基-1-甲基-1-环己胺 顺式-2-甲基环己胺 顺式-2-(苯基氨基)环己醇 顺式-2-(苯基氨基)环己醇 顺式-2-(氨基甲基)-1-苯基环丙烷羧酸盐酸盐 顺式-1,3-二氨基环戊烷 顺式-1,2-环戊烷二胺二盐酸盐 顺式-1,2-环戊烷二胺 顺式-1,2-环丁腈 顺式-1,2-双氨甲基环己烷 顺式--N,N'-二甲基-1,2-环己二胺 顺式-(R,S)-1,2-二氨基环己烷铂硫酸盐 顺式-(2-氨基-环戊基)-甲醇 顺-2-戊烯腈 顺-1,3-环己烷二胺 顺-1,3-双(氨甲基)环己烷